Next Article in Journal
An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature
Next Article in Special Issue
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Previous Article in Journal
Recurrent Pneumonia in Children: A Reasoned Diagnostic Approach and a Single Centre Experience
Previous Article in Special Issue
From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers
Article Menu
Issue 2 (February) cover image

Export Article

Correction published on 4 September 2017, see Int. J. Mol. Sci. 2017, 18(9), 1899.

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(2), 295;

Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference

Department of Dermatology, XiangYa Hospital, Central South University, Changsha 410008, China
Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha 410008, China
Authors to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 20 December 2016 / Revised: 21 January 2017 / Accepted: 25 January 2017 / Published: 29 January 2017
(This article belongs to the Special Issue Next-Generation Sequencing for Clinical Application)
Full-Text   |   PDF [2634 KB, uploaded 10 October 2017]   |  


Psoriasis vulgaris is an immune-mediated inflammatory skin disease. Although acitretin is a widely used synthetic retinoid for moderate to severe psoriasis, little is known about patients’ genetics in response to this drug. In this study, 179 patients were enrolled in either the discovery set (13 patients) or replication set (166 patients). The discovery set was sequenced by whole exome sequencing and sequential validation was conducted in the replication set by MassArray assays. Four SNPs (single nucleotide polymorphisms) (rs1105223T>C in CRB2, rs11086065A>G in ANKLE1, rs3821414T>C in ARHGEF3, rs1802073 T>G in SFRP4) were found to be significantly associated with acitretin response in either co-dominant or dominant models via multivariable logistic regression analysis, while CRB2 rs1105223CC (OR = 4.10, 95% CI = 1.46–11.5, p = 0.007) and ANKLE1 rs11086065AG/GG (OR = 2.76, 95% CI = 1.42–5.37, p = 0.003) were associated with no response to acitretin after 8-week treatment. Meanwhile, ARHGEF3 rs3821414CT/CC (OR = 0.25, 95% CI = 0.10–0.68, p = 0.006) and SFRP4 rs1802073GG/GT (OR = 2.40, 95% CI, 1.23–4.70, p = 0.011) were associated with a higher response rate. Four new genetic variations with potential influences on the response to acitretin were found in this study which may serve as genetic markers for acitretin in psoriasis patients. View Full-Text
Keywords: whole exome sequencing; genetic variation; psoriasis; acitretin whole exome sequencing; genetic variation; psoriasis; acitretin

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zhou, X.; He, Y.; Kuang, Y.; Li, J.; Zhang, J.; Chen, M.; Chen, W.; Su, J.; Zhao, S.; Liu, P.; Chen, M.; Shen, M.; Chen, X.; Zhu, W.; Chen, X. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference. Int. J. Mol. Sci. 2017, 18, 295.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top